Biotech - Spark Newswire

1 minute read

Monopar, National University of Singapore Team Up For Preclinical Assessment Of MNPR-202 In Cancer Settings

Today, 10:27 PM

Monopar Therapeutics Inc (NASDAQ:MNPR) collaborates with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs…

MNPR

1 minute read

FDA
News

Novartis Says Its Candidate For Treatment Of Men With Metastatic Castration-Resistant Prostate Cancer Showed Improvements In Overall Survival

By Benzinga Newsdesk

Today, 10:27 PM

-Reuters

NVS

1 minute read

FDA
News

Adicet ClinicalTrials.gov Study Record Detail For Co.’s ‘Long-Term Follow-up Study for Subjects Treated With Adicet Bio T Cell Investigational Products,’ Shows Not Yet Recruiting

By Benzinga Newsdesk

Today, 10:27 PM

https://clinicaltrials.gov/ct2/show/NCT04911478

ACET

3 minute read

FDA
News

Mirum Pharma Highlights Presentation Of Analyses From Clinical Studies Evaluating Maralixibat In Patients With Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis Type 2

By Benzinga Newsdesk

Today, 10:27 PM

- Maralixibat-treated patients achieving serum bile acid control have improved five-year native liver survival; nominated for prestigious Alex Mowat Prize for best oral presentation in hepatology. - Safety data from

MIRM

1 minute read

FDA
News

Zynerba Pharmaceuticals Announces Presentation Of Efficacy, Safety Findings In Children, Adolescents With Autism Spectrum Disorder (ASD) And Related Disorders At 2021 American Society Of Clinical Psychopharmacology Annual Meeting

By Benzinga Newsdesk

Today, 10:27 PM

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster today from 10:00

ZYNE

4 minute read

Actinium Activates Radiation Inside the Body for Target Conditioning of Cancer Cells

By Dinah Berkeley

Today, 10:27 PM

Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company, is developing antibody radiation-conjugates (ARCs) to combine the targeting ability of antibodies with the cell-killing ability of radiation.

ATNM

2 minute read

FDA
News

COMPASS Pathways, Kings College London Publish Cognition Results From COMP360 Psilocybin Study In Healthy Volunteers

By Benzinga Newsdesk

Today, 10:27 PM

COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I

CMPS

1 minute read

Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs

By Vandana Singh

Today, 10:27 PM

Auris Medical Holding Ltd (NASDAQ:EARS) has acquired privately-held Trasir Therapeutics Inc, focused on extrahepatic oligonucleotide delivery. The purchase price comprises 0.77…

EARS

1 minute read

Acadia Pharmaceuticals Highlights Publication Of NUPLAZID In Efficacy Data In Parkinsonism And Related Disorders Journal

By Bill Haddad

Today, 10:27 PM

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced publication of open-label extension (OLE) data from patients experiencing hallucinations and delusions associated with Parkinson's disease psychosis (PDP) who

ACAD

2 minute read

FDA
News

PDS Biotechnology Says Expands VERSATILE-002 Study Of PDS0101, KEYTRUDA In Advanced Head And Neck Cancer To Include Patients Who Have Failed Prior Treatment With Checkpoint Inhibitors

By Benzinga Newsdesk

Today, 10:27 PM

PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell

MRK